A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).
- Citation:
- Lung Cancer vol 68 (2) 234-9
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- CCP
- Primary Committee:
- Symptom Inter
- Sec. Committees:
- Pharmas:
- Grants:
- K24 CA131099, UG1 CA189823
- Corr. Author:
- Authors:
- Aminah Jatoi Howard L Ritter Amylou Dueck Phuong L Nguyen Daniel A Nikcevich Ronnie F Luyun Bassam I Mattar Charles L Loprinzi
- Networks:
- Study
- NCCTG-N01C9
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Fatigue, Female, Genetic Association Studies, Genotype, Humans, Infliximab, Lung Neoplasms, Male, Polymorphism, Genetic, Quality of Life, Taxoids, Tumor Necrosis Factor-alpha, Weight Loss